Oda Hitomi, Mori Akihiro, Shono Saori, Onozawa Eri, Sako Toshinori
School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan.
J Vet Med Sci. 2016 Jun 1;78(5):851-4. doi: 10.1292/jvms.15-0410. Epub 2016 Jan 17.
This study investigated the changes in lymphocyte subsets during the trilostane medication of Pituitary-dependent hyperadrenocorticism (PDH) dogs. The cortisol level and lymphocyte subsets of eight dogs with PDH were monitored 0, 1, 3, 6, 9 and 12 months after the initiation of trilostane treatment. White blood cells (WBC), lymphocytes, CD3(+) (T lymphocyte), CD4(+) (helper T lymphocyte), CD8(+) (cytotoxic T lymphocyte) and CD21(+) (B lymphocyte) cells were measured. Although the post-ACTH stimulation test cortisol level was significantly lower during trilostane treatment, changes in the CD3(+), CD4(+), CD8(+) and CD21(+) counts were not observed. Meanwhile, significant decrease was observed in WBC counts during trilostane treatment. These indicate that long-term trilostane treatment has little effect on the lymphocyte subsets in PDH dogs.
本研究调查了垂体依赖性肾上腺皮质功能亢进症（PDH）犬使用曲洛司坦治疗期间淋巴细胞亚群的变化。对8只患有PDH的犬在开始曲洛司坦治疗后的0、1、3、6、9和12个月监测其皮质醇水平和淋巴细胞亚群。检测白细胞（WBC）、淋巴细胞、CD3(+)（T淋巴细胞）、CD4(+)（辅助性T淋巴细胞）、CD8(+)（细胞毒性T淋巴细胞）和CD21(+)（B淋巴细胞）细胞。尽管在曲洛司坦治疗期间促肾上腺皮质激素刺激试验后的皮质醇水平显著降低，但未观察到CD3(+)、CD4(+)、CD8(+)和CD21(+)计数的变化。同时，在曲洛司坦治疗期间观察到白细胞计数显著下降。这些表明长期曲洛司坦治疗对PDH犬的淋巴细胞亚群影响很小。
